Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Overview
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Companies Involved in Therapeutics Development
Abeo Therapeutics Inc
Amicus Therapeutics Inc
ArmaGen Inc
Deli Therapeutics Inc
Esteve Pharmaceuticals SA
JCR Pharmaceuticals Co Ltd
Lysogene SAS
Tega Therapeutics Inc
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Drug Profiles
AGT-184 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DNL-126 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EGT-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate SGSH for Mucopolysaccharidosis Type IIIA - Drug Profile
Product Description
Mechanism Of Action
History of Events
JR-441 - Drug Profile
Product Description
Mechanism Of Action
History of Events
LYSSAF-302 - Drug Profile
Product Description
Mechanism Of Action
History of Events
rebisufligene etisparvovec - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombint Enzyme to Replace Sulphamidase for Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Drug Profile
Product Description
Mechanism Of Action
History of Events
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Dormant Products
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Discontinued Products
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Product Development Milestones
Featured News & Press Releases
Feb 24, 2022: Lysogene provides update on efficacy, safety and timelines of the AAVance Phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA
Feb 11, 2022: Lysogene reports additiol positive biomarker data with LYS-SAF302 presented at the WORLDSymposium 2022
Feb 03, 2022: JCR pharmaceuticals to present posters on JR-441 at the 18th annual WORLDSymposium 2022
Jan 21, 2022: EC grants orphan drug desigtion to JR-441 for the treatment of mucopolysaccharidosis type III A (MPS IIIA)
Nov 17, 2021: Abeo Therapeutics announces presentation on pivotal Transpher A study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
Oct 13, 2021: Abeo Therapeutics announces clinical data presentations at upcoming scientific congresses
Jul 28, 2021: Abeo Therapeutics announces successful Type B meeting with U.S. FDA for ABO-102 AAV-based gene therapy in Sanfilippo Syndrome Type A (MPS IIIA)
Jul 26, 2021: Abeo Therapeutics announces new MRI data showing increased brain volume in young patients with Sanfilippo Syndrome Type A (MPS IIIA) after treatment with ABO-102 gene therapy
Feb 15, 2021: Lysogene reports LYS-SAF302 biomarker data presented at the WORLDSymposium 2021
Feb 12, 2021: New positive interim data on ABO-102 presented at WORLDSymposium
Feb 02, 2021: Abeo Therapeutics announces clinical investigator webir to review ABO-102 Clinical Data presented at the 17th Annual WORLDSymposium
Dec 28, 2020: Lysogene reports positive biomarker data with LYS-SAF302
Dec 21, 2020: Abeo Therapeutics announces acceptance of late-breaker abstracts highlighting new clinical data for novel AAV-based gene therapies including rebisufligene etisparvovec at WORLDSymposium
Oct 15, 2020: Lysogene provides update on the AAVance clinical trial evaluating LYS-SAF302 in patients with MPS IIIA
Jun 05, 2020: Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Abeona Therapeutics Inc, 2022
Pipeline by Amicus Therapeutics Inc, 2022
Pipeline by ArmaGen Inc, 2022
Pipeline by Denali Therapeutics Inc, 2022
Pipeline by Esteve Pharmaceuticals SA, 2022
Pipeline by JCR Pharmaceuticals Co Ltd, 2022
Pipeline by Lysogene SAS, 2022
Pipeline by Tega Therapeutics Inc, 2022
Dormant Projects, 2022
Discontinued Products, 2022